⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AKTX News
Akari Therapeutics plc ADR (0.01 USD)
Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums
globenewswire.com
AKTX
Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
globenewswire.com
AKTX
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
accessnewswire.com
AIM
AKTX
CNSP
DARE
NVNO
ERNA
GRI
MBRX
OTLK
Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy
globenewswire.com
AKTX
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
globenewswire.com
AKTX
Form 8-K
sec.gov
AKTX
Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation
globenewswire.com
AKTX
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity
globenewswire.com
AKTX
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
globenewswire.com
AKTX
Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board
globenewswire.com
AKTX